Literature DB >> 26264359

Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease.

S Singh1,2, N S Ding3, K L Mathis4, P S Dulai2, A M Farrell5, J H Pemberton4, A L Hart3, W J Sandborn2, E V Loftus1.   

Abstract

BACKGROUND: Temporary faecal diversion is sometimes used for management of refractory perianal Crohn's disease (CD) with variable success. AIMS: To perform a systematic review with meta-analysis to evaluate the effectiveness, long-term outcomes and factors associated with success of temporary faecal diversion for perianal CD.
METHODS: Through a systematic literature review through 15 July 2015, we identified 16 cohort studies (556 patients) reporting outcomes after temporary faecal diversion. We estimated pooled rates [with 95% confidence interval (CI)] of early clinical response, attempted and successful restoration of bowel continuity after temporary faecal diversion (without symptomatic relapse), and rates of re-diversion (in patients with attempted restoration) and proctectomy (with or without colectomy and end-ileostomy). We identified factors associated with successful restoration of bowel continuity.
RESULTS: On meta-analysis, 63.8% (95% CI: 54.1-72.5) of patients had early clinical response after faecal diversion for refractory perianal CD. Restoration of bowel continuity was attempted in 34.5% (95% CI: 27.0-42.8) of patients, and was successful in only 16.6% (95% CI: 11.8-22.9). Of those in whom restoration was attempted, 26.5% (95% CI: 14.1-44.2) required re-diversion because of severe relapse. Overall, 41.6% (95% CI: 32.6-51.2) of patients required proctectomy after failure of temporary faecal diversion. There was no difference in the successful restoration of bowel continuity after temporary faecal diversion in the pre-biological or biological era (13.7% vs. 17.6%, P = 0.60), in part due to selection bias. Absence of rectal involvement was the most consistent factor associated with restoration of bowel continuity.
CONCLUSIONS: Temporary faecal diversion may improve symptoms in approximately two-thirds of patients with refractory perianal Crohn's disease, but bowel restoration is successful in only 17% of patients.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 26264359      PMCID: PMC6698449          DOI: 10.1111/apt.13356

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  44 in total

Review 1.  Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy.

Authors:  M Fumery; P S Dulai; P Meirick; A M Farrell; S Ramamoorthy; W J Sandborn; S Singh
Journal:  Aliment Pharmacol Ther       Date:  2016-12-08       Impact factor: 8.171

2.  Crohn's disease with anorectal stenosis successfully treated with vedolizumab.

Authors:  Darja Urlep; Rok Orel
Journal:  World J Pediatr       Date:  2017-08       Impact factor: 2.764

Review 3.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 4.  Current management of intestinal bowel disease: the role of surgery.

Authors:  Gaspare Solina; Stefano Mandalà; Camillo La Barbera; Vincenzo Mandalà
Journal:  Updates Surg       Date:  2016-04-11

5.  Molecular classification of Crohn's disease reveals two clinically relevant subtypes.

Authors:  Matthew Weiser; Jeremy M Simon; Bharati Kochar; Adelaide Tovar; Jennifer W Israel; Adam Robinson; Gregory R Gipson; Matthew S Schaner; Hans H Herfarth; R Balfour Sartor; Dermot P B McGovern; Reza Rahbar; Timothy S Sadiq; Mark J Koruda; Terrence S Furey; Shehzad Z Sheikh
Journal:  Gut       Date:  2016-10-14       Impact factor: 23.059

Review 6.  Recent advances in the management of perianal fistulizing Crohn's disease: lessons for the clinic.

Authors:  Nicole Lopez; Sonia Ramamoorthy; Willam J Sandborn
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2019-04-26       Impact factor: 3.869

Review 7.  Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease.

Authors:  Fernando Bermejo; Iván Guerra; Alicia Algaba; Antonio López-Sanromán
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

8.  Fecal Diversion in Patients With Crohn's Disease.

Authors:  Feza Remzi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-08

9.  The Use of Temporary Fecal Diversion in Colonic and Perianal Crohn's Disease Does Not Improve Outcomes.

Authors:  Andrea C Bafford; Anastasiya Latushko; Natasha Hansraj; Guruprasad Jambaulikar; Leyla J Ghazi
Journal:  Dig Dis Sci       Date:  2017-05-26       Impact factor: 3.199

10.  ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Authors:  Gary R Lichtenstein; Edward V Loftus; Kim L Isaacs; Miguel D Regueiro; Lauren B Gerson; Bruce E Sands
Journal:  Am J Gastroenterol       Date:  2018-03-27       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.